Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

Thomas Fremming Dejgaard,Tanja Stenbæk Hansen,Sten Madsbad,Thomas Almdal,Christian Seerup Frandsen,Henrik Ullits Andersen,Lise Tarnow,Filip Krag Knop,Jens Juul Holst

doi:10.1136/bmjopen-2015-007791

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

Thomas Fremming Dejgaard, Tanja Stenbæk Hansen + Show 7 more

Open Access

https://doi.org/10.1136/bmjopen-2015-007791

Copy DOI

Journal: BMJ Open	Publication Date: Apr 1, 2015
Citations: 12	License type: open-access

Affiliation: Hvidovre Hospital, University of Copenhagen, Gentofte Hospital, Nordsjællands Hospital

#Glucagon-like Peptide-1 Receptor Agonist Liraglutide #Placebo-controlled Study + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionIntensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: BMJ Open

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.